Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD)

Q: What does CUSIP 140755307 represent in this 13F holders report?

CUSIP 140755307 is the security identifier for TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q4 2025?

64 institutional investors reported TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 140755307

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 9,470,889
Total 13F shares: 2,824,911
Share change: +220,972
Total reported value: $12,111,919
Put/Call ratio: 0%
Price per share: $4.30
Number of holders: 64
Value change: -$18,315,547
Number of buys: 42
Number of sells: 21

Quarterly Holders Quick Answers

What is CUSIP 140755307?
CUSIP 140755307 identifies TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 140755307:

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Top shareholders of TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Slate Path Capital LP	13F 13D/G	Company	7.5% from 13D/G	704,118	$27,439,478	—	30 Sep 2025	13F 13D/G
Sporos Bioventures LLC	13D/G	—	9%	837,636	$19,544,812	$0	15 Apr 2025	13D/G
VANGUARD GROUP INC	13F	Company	4.4%	419,167	$16,334,938	—	30 Sep 2025	13F
BlackRock, Inc.	13F	Company	3.5%	329,914	$12,856,749	—	30 Sep 2025	13F
CSL LTD	3/4/5	10%+ Owner	— class O/S missing	7,396,770	$9,024,059	—	09 Aug 2022	3/4/5
Vifor (International) Ltd	3/4/5 13D/G	10%+ Owner	2.2% from 13D/G	7,396,770	$9,024,059	—	20 Oct 2021	3/4/5 13D/G
Samuel D. Tweardy	13D/G	—	3.4%	315,658	$7,365,343	-$14,730,686	07 Jul 2025	13D/G
683 Capital Management, LLC	13F	Company	1.9%	176,030	$6,768,424	—	30 Sep 2025	13F
Vestal Point Capital, LP	13F	Company	1.8%	167,000	$6,507,990	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.6%	147,919	$5,765,883	—	30 Sep 2025	13F
Solas Tvardi Sidecar LLC	13D/G	—	8.1%	761,287	$4,050,047	$0	15 Apr 2025	13D/G
David J. Tweardy	13D/G	—	7%	652,398	$3,470,757	$0	15 Apr 2025	13D/G
Invesco Ltd.	13F	Company	0.87%	82,614	$3,219,468	—	30 Sep 2025	13F
FMR LLC	13F	Company	0.87%	82,221	$3,204,152	—	30 Sep 2025	13F
Parkman Healthcare Partners LLC	13F	Company	0.69%	65,000	$2,533,050	—	30 Sep 2025	13F
STATE STREET CORP	13F	Company	0.66%	62,864	$2,449,810	—	30 Sep 2025	13F
Shaheen Wirk	3/4/5	Director	— mixed-class rows	451,194 mixed-class rows	$2,225,966	—	17 Apr 2025	3/4/5
Ronald A. DePinho	13D/G	—	4.5%	426,190	$1,939,164	$0	31 Dec 2025	13D/G
UBS Group AG	13F	Company	0.51%	48,479	$1,889,227	—	30 Sep 2025	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	0.46%	43,225	$1,684,478	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.45%	42,383	$1,651,666	—	30 Sep 2025	13F
Wallace L. Hall Jr.	3/4/5	Director	— mixed-class rows	258,756 mixed-class rows	$1,250,632	—	17 Apr 2025	3/4/5
Chalmers Derek T.	3/4/5	President & CEO, Director	— class O/S missing	991,405	$1,209,514	—	07 Sep 2021	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.32%	30,175	$1,175,920	—	30 Sep 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.25%	24,029	$936,410	—	30 Sep 2025	13F
SILVERCREST ASSET MANAGEMENT GROUP LLC	13F	Company	0.24%	22,366	$871,603	—	30 Sep 2025	13F
Duncan Williams Asset Management, LLC	13F	Company	0.24%	22,030	$858,509	—	30 Sep 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.21%	20,189	$786,765	—	30 Sep 2025	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.2%	19,132	$745,573	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.16%	15,362	$598,657	—	30 Sep 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.16%	15,274	$595,228	—	30 Sep 2025	13F
Monaco Asset Management SAM	13F	Company	0.14%	13,590	$529,602	—	30 Sep 2025	13F
Bank of New York Mellon Corp	13F	Company	0.1%	9,666	$376,684	—	30 Sep 2025	13F
Squarepoint Ops LLC	13F	Company	0.09%	8,164	$318,151	—	30 Sep 2025	13F
Martin Vogelbaum	3/4/5	Director	— mixed-class rows	801,007 mixed-class rows	$308,255	—	04 Jun 2024	3/4/5
BARCLAYS PLC	13F	Company	0.07%	6,669	$259,891	—	30 Sep 2025	13F
Nuveen, LLC	13F	Company	0.06%	5,951	$231,910	—	30 Sep 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.04%	3,982	$155,172	—	30 Sep 2025	13F
Jeffrey L. Ives	3/4/5	Director	— mixed-class rows	393,485 mixed-class rows	$148,864	—	04 Jun 2024	3/4/5
MORGAN STANLEY	13F	Company	0.04%	3,786	$147,541	—	30 Sep 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.04%	3,554	$138,499	—	30 Sep 2025	13F
Lisa von Moltke	3/4/5	Director	— mixed-class rows	378,009 mixed-class rows	$137,257	—	04 Jun 2024	3/4/5
DEUTSCHE BANK AG\	13F	Company	0.03%	3,030	$118,079	—	30 Sep 2025	13F
SIMPLEX TRADING, LLC	13F	Company	0.03%	2,988	$116,000	—	30 Sep 2025	13F
Helen M. Boudreau	3/4/5	Director	— mixed-class rows	345,647 mixed-class rows	$112,985	—	04 Jun 2024	3/4/5
MetLife Investment Management, LLC	13F	Company	0.03%	2,819	$109,856	—	30 Sep 2025	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.03%	3,000	$108,030	—	30 Sep 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.03%	2,669	$104,000	—	30 Sep 2025	13F
Frederique Ph.D. Menzaghi	3/4/5	CHIEF SCIENTIFIC OFF,SVP-R&D	— class O/S missing	167,247	$91,986	—	01 Feb 2024	3/4/5
Arax Advisory Partners	13F	Company	0.02%	2,227	$86,787	—	30 Sep 2025	13F

Institutional Holders of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) as of Q4 2025

As of 31 Dec 2025, Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) was held by 64 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,824,911 shares. The largest 10 holders included Slate Path Capital LP, VANGUARD GROUP INC, BlackRock, Inc., AMERICAN FINANCIAL GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, SILVERCREST ASSET MANAGEMENT GROUP LLC, MORGAN STANLEY, and Duncan Williams Asset Management, LLC. This page lists 64 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.